School of Medicine
Area of interest
Parker’s research involves methodological development, integrated analysis, and machine learning for high throughput studies in cancer. He previously lead the development of algorithms and content resulting in Prosigna™, the only CE marked and FDA 510(k) cleared breast cancer diagnostic assay for FFPE tissue. He is currently involved in similar diagnostic development activities across multiple solid tumors types with the goal of optimizing treatment for individual tumors. Dr. Parker currently directs the sequencing and related genomic analysis in the Bioinformatics Shared Resource at the Lineberger Comprehensive Cancer Center. The Bioinformatics Shared Resource provides consultation and analytical services primarily for the Cancer Center, but is also involved in collaborations across multiple departments and institutions. In this role he lead processing and dissemination of 10K RNA-seq samples as part of TCGA, 2k cancer samples as part of the UNCseq program, and leads our shared resource activity for multiple collaborative studies.